Analyst Ratings For Mateon Therapeutics (NASDAQ:MATN)
Today, Maxim Group reiterated its Hold rating on Mateon Therapeutics (NASDAQ:MATN).
There are 1 hold rating, 3 buy ratings on the stock.
The current consensus rating on Mateon Therapeutics (NASDAQ:MATN) is Buy (Score: 2.75) with a consensus target price of $2.00 per share, a potential 471.43% upside.
Some recent analyst ratings include
- 8/1/2017-Maxim Group Reiterated Rating of Hold.
- 4/20/2017-Roth Capital initiated coverage with a Buy rating.
- 3/13/2017-HC Wainwright initiated coverage with a Buy rating.
- 3/13/2017-Rodman & Renshaw Reiterated Rating of Buy .
- 8/7/2015-MLV & Co. Reiterated Rating of Buy.
Recent Insider Trading Activity For Mateon Therapeutics (NASDAQ:MATN)
Mateon Therapeutics (NASDAQ:MATN) has insider ownership of 2.30% and institutional ownership of 8.60%.
- On 12/16/2016 Donald Rogers Reynolds, Director, bought 30,000 with an average share price of $0.35 per share and the total transaction amounting to $10,500.00. View SEC Filing
- On 6/28/2013 Peter Langecker, CEO, bought 3,000 with an average share price of $2.75 per share and the total transaction amounting to $8,250.00. View SEC Filing
- On 6/25/2013 Peter Langecker, CEO, bought 2,000 with an average share price of $2.79 per share and the total transaction amounting to $5,580.00. View SEC Filing
Recent Trading Activity for Mateon Therapeutics (NASDAQ:MATN)
Shares of Mateon Therapeutics closed the previous trading session at 0.350 down -0.010 -2.78% with 988,527 shares trading hands.